The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse ...

The majority of patients with skin of color and scalp psoriasis who were treated with guselkumab achieved significant scalp clearance.

Medicare may cover Tremfya. However, the medication can be high cost, so a person should check with Medicare or their plan provider beforehand.

Over a follow-up of 48 weeks, both guselkumab regimens were superior to placebo for both coprimary composite endpoints. The first coprimary endpoint was clinical response at week 12 and clinical ...

Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately ...

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that ...

In this video, Philip J. Mease, MD, director of rheumatology research at Providence Swedish Medical Center, in Seattle, discusses results from phase 3b clinical trials of guselkumab.The data, ...

Guselkumab is the first biologic shown in identically designed, 48-week, double-blind trials to outperform another leading biologic—ustekinumab, a monoclonal antibody that blocks both IL-12 and ...

Guselkumab provides greater benefits than TNF‑alpha inhibitors and ustekinumab, and similar benefits to secukinumab and ixekizumab 3.4 The committee noted that the results of the network meta-analysis ...

In the guselkumab group, data were available for 302 patients (mean age, 49.7 [13.8] years; 63.9% men). Patients’ mean PASI score decreased over time from 15.7 (9.8) at baseline to 2.4 (4.7) at week ...